• Featured Story

    20141013-biotech-etf

    There are more than 1,000 biotech companies in North America alone. They cover a wide range of sectors including pharmaceuticals, biologics, generics, and medical devices.

    But finding the right stocks in such a broad industry is no easy task.

    That's why we've targeted the best biotech ETF to buy now. It offers investors an excellent way to play the entire industry, without having to pick a specific sector.

    Here’s the pick…

biotech stocks

Ebola Stocks Surge as Race for Treatment Heats Up – but Steer Clear of Overhyped Plays

Ebola Stocks

The number of companies racing to find an Ebola treatment is increasing. All drugs remain in the testing stage, but that hasn't stopped investors from piling into these "Ebola stocks."

Chimerix (Nasdaq: CMRX) climbed 5% Monday on reports that the Ebola patient in Dallas is being treated with its drug, brincidofovir.

Read More…

Investing in Biotech Stocks: Use This One Simple Strategy to Limit Risk and Maximize Gains

20141006-investing-in-biotech-stocks

It's a common thought that investing in biotech stocks is just too risky for the average investor - but that's not the case.

It's true that biotechnology stocks can be very volatile - especially when companies have developmental drugs going through clinical trials - so they aren't the right stocks for every investor. But when investors are able to limit risk, they can find their portfolio's biggest profits from biotech.

Money Morning's BioScience Investment Strategist Ernie Tremblay recommends investors use this one simple strategy when investing in biotech.

It helps limit risk and maximize profits. Take a look…

The Keryx (Nasdaq: KERX) Media Blunder Will Add to Our 700% Gain

Money

On August 29, 2012, shares of Keryx Biopharmaceuticals - a company focused on pharmaceutical products for patients with renal disease - closed for the day's session at $2.06. Exactly two years later, on August 29, 2014, the same stock closed at $18.19./

That's right: Investors made a 780% profit over their original position, and it looked like the price per share (PPS) was destined to climb considerably higher.

In fact, analysts had set their average first-year target for the stock at about $23. And there was every reason to believe Keryx would reach and break through that target after the FDA approved it for marketing in the United States on its PDUFA date, set for September 7.

But then something odd happened...

The FDA rendered its decision early, on September 5, and although the news was good - KERX's drug had been approved - the stock fell more than 11% by the session opening the following Monday and continued falling over the next few weeks - giving traders today an opportunity to take advantage of the situation and make huge profits.

Here's why...

Avoid These Biotech Stocks to Minimize Risk

biotech stocks

Investing in biotech stocks is risky for those who haven't done enough research. But with just a couple of tips, investors can drastically reduce the risk - and go on to benefit from massive windfalls generated by a company's breakthrough drug development.

To find out the best way to minimize risk in biotech investing, we turned to Money Morning's BioScience Investment Specialist Ernie Tremblay.

According to Tremblay, there are a couple of types of biotech stocks that are especially risky…

This New Alzheimer's Drug Could Be the Fastest Route to a Treatment Breakthrough

new Alzheimer’s drug

Just last week, two major pharmaceutical companies announced that they are working together on a new Alzheimer's drug - and that's great news. But it may be a decade away from becoming reality.

But another biotech company is zooming ahead in the race for the cure - and its drug is in late-stage phase 3 trials.

In other words, there is a way to both fight Alzheimer’s and supercharge your portfolio – today…

Eight New Picks from Our "Stocks to Buy Now" List (and None Are Alibaba)

stocks to buy

Best stocks to buy for the week ending Sept. 19, 2014:Last week, U.S. market history was made when Alibaba debuted as the biggest IPO of all time. While we like BABA stock, it's not the only way to profit.

You can find all of last week's recommendations here in our newest list of the best stocks to buy now.

Including 2 top biotech picks, 2 energy stocks that take advantage of recent EPA rule changes, and more...

Two of the Best Biotech Stocks to Buy Now

biotech stocks to buy

Since April 11, Gilead Sciences (Nasdaq: GILD) has scored peak gains of a 74.2% - or more than 175% annualized gains.

Some investors don't want to risk it all during a sell-off - but they still want to take advantage of the growth biotech stocks offer.

Here are two biotech stocks to buy – one appeals to risk takers and one to investors who favor a more conservative approach – and both offer plenty of upside potential…

Three of the Best Biotech Penny Stocks to Buy Now

penny stocks to buy

For investors looking for the best penny stocks to buy, the biotech sector offers some of the best investment opportunities on the market.

Despite the fact that biotech stocks have been up and down in 2014, Money Morning's Bioscience Investment Specialist Ernie Tremblay sees great profit opportunities for the rest of 2014.

Here are the three best biotech penny stocks to buy now and why they could take off…

The Clear Map to This "Hidden" Investment Treasure

Treasure chest 1

Ask any bioscience researcher about leading trends in medical science, and at some point, you're likely to hear a lot of enthusiasm around the phrase personalized medicine.

That's treatment based on the individual's particular disease state, risk factors, and most importantly, genetic profile. And it's already yielding unheard-of profits for traders and investors.

As scientists reach the discovery limits of "one-size-fits-all" drugs and the ailments that respond to them, such as infections and circulatory diseases, they find themselves up against tougher, wilier, more intractable challenges... Full Story

Biogen Idec (Nasdaq: BIIB) Stock Gains on FDA Approval of New MS Drug

Lab worker

Biogen Idec Inc. (Nasdaq: BIIB) stock was up 1.6% this morning following news that the company's multiple sclerosis (MS) drug Plegridy was approved by the U.S. Food and Drug Administration on Friday.

The stock is up 14% in the last month and is still showing bullish signs.

Today's FDA approval is a big win for BIIB stock, but it's just one reason this stock is continuing higher...

Cerulean Pharma Inc. (Nasdaq: CERU) Stock Shows the Staggering Gains Biotech Has to Offer

Short Selling Biotech Stocks

One of yesterday's (Wednesday) biggest stock gainers, Cerulean Pharma Inc. (Nasdaq: CERU), is a biotech company that posted a 30.6% gain by day's end.

This comes at a time when short sellers are adding to their positions, waiting for a downfall of biotech, and even the country's head central banker Janet Yellen has little faith in the sector. Biotech has been on a rally over the last year, a rally that a lot of traders feel has run its course.

But biotech is still strong, and here's why...

Trouble Ahead for Pfizer Stock (NYSE: PFE) as Lipitor Claims Inevitably Amass

pfizer stock

Updated August 14, 2014: Pfizer stock (NYSE: PFE) will soon feel the pressure from the wave of lawsuits being filed claiming that Pfizer's blockbuster drug Lipitor - the world's best-selling drug of all time - causes type-2 diabetes in women.

"This will be a huge overhang on Pfizer stock," Money Morning Capital Wave Strategist Shah Gilani said. "Investors have to watch developments closely."

With a market cap of more than $180 billion, the world's largest pharmaceutical firm's pockets run deep. Lipitor alone brought in global sales of more than $125 billion for Pfizer over the 14-and-a-half years since its 1996 market debut (Pfizer's patent on Lipitor expired on November 30, 2011). More than 29 million patients took the drug just in the United States.

Here’s why there’s a recent spike in claims, and how Gilani recommends playing PFE stock in coming months…